ArticleBMC public health2025
Polycyclic aromatic hydrocarbons are associated with sleep-related disorders in adults: the potential mediating role of inflammation.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between urinary polycyclic aromatic hydrocarbon metabolites and sleep disturbances: A cross-sectional study integrating machine learning and network toxicology.The Journal of international medical research · 2026Article
- Association between vitamin B6 status and liver fibrosis: evidence from NHANES 2005-2010.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe evidence on the effects of polycyclic aromatic hydrocarbons (PAHs) on sleep disorders is limited. This study aimed to explore the association between PAH exposure and sleep-related disorders, and the potential mediating roles of inflammation in these relationships were further been examined.
methodsThis study utilized data from adult participants (≥ 20 years of age) in the US National Health and Nutrition Examination Survey 2005-2008. Weighted logistic regression models were used to estimate the associations between each urinary PAH biomarker and sleep-related disorders. Structural Equation Modelling (SEM) was applied to evaluate the association between PAH exposure and sleep-related disorders and to assess the mediating effect of inflammatory markers that include C-reactive protein (CRP) and white blood cell counts (WBC).
resultsOne or more urinary PAH metabolites were associated with an increased risk of long sleep-onset latency, obstructive sleep apnea (OSA), sleep problems, and daytime sleepiness. The latent PAH exposure variable in SEM was positively associated to long sleep-onset latency (β = 0.054, p = 0.035), OSA (β = 0.071, p = 0.002), sleep problems (β = 0.089, p < 0.001) and daytime sleepiness (β = 0.066, p = 0.003). Mediation analysis suggested that WBC mediated the link between PAH exposure and sleep problems (Indirect effect = 0.009, 95%CI: 0.002 ~ 0.017, Proportion: 10.8%), as well as daytime sleepiness (Indirect effect = 0.011, 95%CI: 0.005 ~ 0.019, Proportion: 15.7%).
conclusionsPAH exposure was associated with an increased risk of long sleep-onset latency, obstructive sleep apnea, sleep problems, and daytime sleepiness. Inflammation may be one potential mechanism by which PAH exposure contributes sleep problems and daytime sleepiness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.